SUWANEE, GA, April 19, 2018 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB: SNWV) and Premier Shockwave, Inc. are pleased to announce that the company will exhibit at the Tribal Public Health Conference in Norman, OK, April 25 – 26, 2018. This will be Premier Shockwave’s first opportunity to present the dermaPACE® System since being selected by SANUWAVE Health, Inc. as its exclusive distributor to the Indian Health Service (IHS) and Tribally operated healthcare services market.
“We are excited to be exhibiting at the 2018 Tribal Public Health Conference. It is an honor to be able to work with the IHS and the Tribal healthcare community to bring a game-changing product to this market which will materially improve patient outcomes and quality of life for those suffering from chronic Diabetic Foot Ulcers “DFUs”. The dermaPACE® System will enable Tribal healthcare to treat their own DFUs internally and not be dependent on out-sourcing area facilities. This will save thousands of dollars per DFU treated by Tribal healthcare.” Stated David Anderson, Executive Vice President of Premier Shockwave Wound Care, Inc. an affiliate of Premier Shockwave, Inc. He added, “Any physician who sees DFUs can prescribe the dermaPACE® System. We expect to see interest from not only podiatrists but also endocrinologists, vascular surgeons, foot & ankle orthopedists and to have their nurses or assistants trained to use the dermaPACE® System on patients in a wound care facility or an in-office setting.”
The Company is using this occasion to formally introduce their lead wound care product, the dermaPACE® System, based upon SANUWAVE’s proprietary Pulsed Acoustic Cellular Expression (PACE®) Technology. PACE® Technology is the newest generation of shockwave technology utilizing the electrohydraulic shockwave principle and has been proven in two double-blind, randomized-control US based clinical trials enrolling 336 subjects to be safe and effective in the treatment of Diabetic Foot Ulcers. Within a few weeks of initial treatment, wounds treated with dermaPACE® reduce in area at superior rates compared to control subjects. The dermaPACE® System continued to exhibit superiority in wound area reduction from baseline and exhibited superiority in wound closure within 20 weeks of initial treatment. The use of the dermaPACE® System allows the clinician to more easily, and more cost-effectively, manage wounds. More importantly, the patient’s quality of life improves significantly.
If you are interested in scheduling a meeting with the team, please contact David Anderson via e-mail at david@premiershockwave.com; otherwise, please stop by our booth.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating System for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE® technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers. The dermaPACE® System is also CE Marked throughout Europe and has license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® System, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron®, Evotron® and orthoPACE® Systems in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
About Premier Shockwave, Inc. and Premier Shockwave Wound Care, Inc.
Premier Shockwave, Inc. is the leading shockwave company for podiatric and orthopedic applications using OssaTron® and dermaPACE® Systems throughout the United States and currently serves over 30 VA Hospitals and Military Treatment Facilities in the continental United States and Alaska. Premier Shockwave, Inc. will manage the dermaPACE® business for Premier Shockwave Wound Care, Inc. For additional information about the company, please go to www.premiershockwave.com.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.